Durvalumab Concurrent and Following Thoracic Radiotherapy vs. Concurrent Chemoradiotherapy and Consolidation Durvalumab in Locally Advanced Non-Small Cell Lung Cancer: A Propensity Matched Analysis of a Prospective Trial
Poster
Shaverdian
9/28/25
4:45-
Kaitlyn Lapen, MD
5
Accelerated Partial Breast Irradiation to 40 Gy in 10 Daily Fractions: Long-Term Results of a Phase II Study
Oral
Braunstein
9/28/25
4:45-
Helen Zhang, MD and David Miller, MD
4
Safety and Activity of KRAS G12C Inhibitors Combined with Thoracic Radiation Therapy Poster
Poster
Shaverdian
9/28/25
4:45-
Amir Safavi, MD
Former Proton Fellow
Long-Term Efficacy and Quality-of-Life Outcomes Following Substantial De-Escalation of Elective Radiotherapy Dose and Volume in Patients Treated With Definitive Chemoradiotherapy For Human Papillomavirus-Associated Oropharyngeal Cancer Oral
Oral
Lee
9/29/25
8:00AM-9:00AM
Sybil Jones, MD
4
Impact of Pain Management Interventions and Radiation Therapy on Pain Control and Treatment Accuracy in Spine Radiation for Metastasis
Poster
Yerramilli
9/29/25
8:00AM-9:00AM
Christopher Jackson, MD
Former Resident/Incoming Faculty
Re-Irradiation with Three-Fraction Stereotactic Body Radiation Therapy for Spinal Metastases
Poster
Yamada
9/29/25
8:00AM-9:00AM
Christopher Jackson, MD
Former Resident/Incoming Faculty
Outcomes Associated with Proton Spine Stereotactic Body Radiation Therapy
Poster
Yamada
9/29/25
10:45AM-12:00PM
Alexander Goglia, MD, PhD
5
Impact of Radiotherapy Site, Modality, and Dose on Subsequent Clonal Hematopoiesis
Oral
Braunstein
9/29/25
10:45AM—12:00PM
Nikhil Mankuzhy, MD
5
Non-Operative Management of Nasal Cavity Cancers with Definitive Proton Beam Therapy or Intensity Modulated Radiation Therapy for Organ Preservation
Poster
Lee
9/29/25
10:45AM—12:00PM
Kaitlyn Lapen, MD
5
Predictors of Skeletal-Related Events and Quality of Life Dimensions among Patients with High-Risk, Asymptomatic Bone Metastases with or without Early Radiation Therapy: Secondary Analysis of a Multicenter, Randomized Phase II Clinical Trial
Oral
Yerramilli & Gillespie
9/29/25
10:45AM—12:00PM
Chris Dee, MD
5
Global Cancer System Characteristics and Cervical Cancer Outcomes
Poster
Dee
9/29/25
10:45AM—12:00PM
Yingzhi Wu, NP-C
APP
Percutaneous Endoscopic Gastrostomy in Patients with Oropharyngeal Cancer in Single Institution Over 5 years
Poster
Lee
9/29/25
10:45AM-12:00PM
Alok DeShane, MD
4
TP53 Mutations and Outcomes after Radiotherapy in Mantle Cell Lymphoma
Oral
Imber & Yahalom
9/29/25
3:00PM -4:00PM
Alexander Terry,MD, PhD
3
Is Partial Breast Irradiation Effective for Early-Stage Breast Cancer Patients with High-Risk Molecular Recurrence Scores?
Poster
Braunstein
9/29/25
5:00PM-6:00PM
Roshal Patel, MD
5
Clinical and Genomic Predictors of Local Failure in NSCLC Patients Treated with Lung SBRT
Oral
Wu
9/29/25
5:00PM-6:00PM
Chris Dee, MD
5
The Impact of National Cancer Systems on Lung Cancer Mortality
Oral
Iyengar
9/30/25
8:00AM-9:00AM
David Miller, MD
4
Early-Stage Breast Cancer with Low Genomic Risk: Optimizing Adjuvant Therapy
Oral
Braunstein
9/30/25
12:45PM-2:00PM
Ross Weber, MD, PhD
4
Toxicity Assessment of Combined External Beam Radiation with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy
Poster
Imber & Gorovets
9/30/25
12:45PM-2:00PM
Christopher Jackson, MD
Former Resident/Incoming Faculty
Impact of Castrate Sensitivity and Genetic Mutations on Local Control after Spine Stereotactic Body Radiation Therapy for Prostate Cancer Spinal Metastases
Oral
Higginson
9/30/25
12:45PM-2:00PM
Chris Dee, MD
4
Osteoradionecrosis as a Complication Following Intensity-Modulated Radiation Therapy or Proton Therapy in the Treatment of Oropharyngeal Carcinoma
Oral
Lee
9/30/25
2:30PM-3:45PM
Alok DeShane, MD
4
When Less Is More: Reducing the Administration of Inappropriate Radiotherapy to Patients with Very Poor Prognosis
Poster
Xu & Yerramilli
9/30/25
2:30PM-3:45PM
Alexandra Dreyfuss, MD
Former Resident
Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
Oral
Yahalom, Moskowitz & Moskowitz
9/30/25
2:30PM-3:45PM
Revathi Ravella, MD
3
Clinical Outcomes and Patterns of Failures of Patients with Oligometastatic Anal Squamous Cell Carcinoma Treated with Definitive-Intent Chemoradiation and Metastasis-Directed Therapy
Poster
Roth O’Brien & Romesser
9/30/25
2:30PM-3:45PM
Elisa Liu, MD
3
Extended-Field Definitive Chemoradiation for Patients with Anal Squamous Cell Carcinoma with Nodal Metastatic Disease
Poster
Roth O’Brien & Romesser
9/30/25
4:00PM-5:00PM
Kevin Boehm,MD, PhD
4
Machine Learning Using >300,000 H&E Images Refines Cancer of Unknown Primary Subtyping
Poster
Shah/Schultz/Sanchez-Vega
9/30/25
4:00PM-5:00PM
Kaitlyn Lapen, MD
5
The Influence of Dose on Response Duration of Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides in the Modern Era of TSEBT Dose Reduction
Poster
Imber & Yahalom
9/30/25
4:00PM-5:00PM
Roshal Patel, MD
5
Bridging Radiation Durably Controls Patients with Bulky Tumors Treated with CAR-T Cell Therapy
Poster
Imber & Yahalom
9/30/25
5:15PM-6:15PM
Nikhil Mankuzhy, MD
5
Response Rate and Local Control of Response-Adapted Very Low Dose Radiotherapy (RA-VLDRT) with 4 Gy for Indolent Non-Hodgkin Lymphoma
Oral
Imber & Yahalom
9/30/25
5:15PM-6:15PM
Alexander Goglia, MD, PhD
5
Prospective Phase II Trial of Short Course Androgen Deprivation, Pelvic SBRT, and Brachytherapy Boost for NCCN High-Risk Prostate Cancer with Low-Intermediate Risk Decipher Genomic Score